X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare VENUS REMEDIES with Abbott India - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs ABBOTT INDIA - Comparison Results

ABBOTT INDIA 
   Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    VENUS REMEDIES ABBOTT INDIA VENUS REMEDIES/
ABBOTT INDIA
 
P/E (TTM) x -9.7 36.7 - View Chart
P/BV x 0.2 10.6 1.4% View Chart
Dividend Yield % 0.0 0.6 -  

Financials

 VENUS REMEDIES   ABBOTT INDIA
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-17
ABBOTT INDIA
Mar-17
VENUS REMEDIES/
ABBOTT INDIA
5-Yr Chart
Click to enlarge
High Rs1435,190 2.8%   
Low Rs654,351 1.5%   
Sales per share (Unadj.) Rs324.21,382.9 23.4%  
Earnings per share (Unadj.) Rs6.4130.2 4.9%  
Cash flow per share (Unadj.) Rs40.6137.9 29.4%  
Dividends per share (Unadj.) Rs040.00 0.0%  
Dividend yield (eoy) %00.8 0.0%  
Book value per share (Unadj.) Rs366.0652.7 56.1%  
Shares outstanding (eoy) m12.3421.25 58.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.33.4 9.3%   
Avg P/E ratio x16.236.6 44.2%  
P/CF ratio (eoy) x2.634.6 7.4%  
Price / Book Value ratio x0.37.3 3.9%  
Dividend payout %030.7 0.0%   
Avg Mkt Cap Rs m1,282101,373 1.3%   
No. of employees `0000.93.1 29.3%   
Total wages/salary Rs m2513,453 7.3%   
Avg. sales/employee Rs Th4,430.19,531.9 46.5%   
Avg. wages/employee Rs Th278.01,119.9 24.8%   
Avg. net profit/employee Rs Th87.6897.3 9.8%   
INCOME DATA
Net Sales Rs m4,00029,387 13.6%  
Other income Rs m23576 3.9%   
Total revenues Rs m4,02329,963 13.4%   
Gross profit Rs m7853,973 19.7%  
Depreciation Rs m422164 256.6%   
Interest Rs m34420 1,684.8%   
Profit before tax Rs m424,365 1.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-371,598 -2.3%   
Profit after tax Rs m792,767 2.9%  
Gross profit margin %19.613.5 145.1%  
Effective tax rate %-87.936.6 -240.0%   
Net profit margin %2.09.4 21.0%  
BALANCE SHEET DATA
Current assets Rs m2,60618,906 13.8%   
Current liabilities Rs m1,9806,297 31.5%   
Net working cap to sales %15.642.9 36.5%  
Current ratio x1.33.0 43.8%  
Inventory Days Days12862 206.3%  
Debtors Days Days4322 199.4%  
Net fixed assets Rs m5,3531,159 462.0%   
Share capital Rs m123213 58.1%   
"Free" reserves Rs m4,39313,657 32.2%   
Net worth Rs m4,51613,869 32.6%   
Long term debt Rs m1,6180-   
Total assets Rs m8,29120,638 40.2%  
Interest coverage x1.1215.0 0.5%   
Debt to equity ratio x0.40-  
Sales to assets ratio x0.51.4 33.9%   
Return on assets %5.113.5 37.8%  
Return on equity %1.819.9 8.8%  
Return on capital %6.331.6 19.9%  
Exports to sales %00-   
Imports to sales %18.40-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m736NA-   
Fx inflow Rs m00-   
Fx outflow Rs m7360-   
Net fx Rs m-7360-   
CASH FLOW
From Operations Rs m9973,072 32.5%  
From Investments Rs m-461-1,554 29.7%  
From Financial Activity Rs m-571-898 63.6%  
Net Cashflow Rs m-35621 -5.7%  

Share Holding

Indian Promoters % 32.9 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 0.2 7.9 2.3%  
FIIs % 0.6 0.1 580.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 66.4 17.1 388.3%  
Shareholders   20,121 18,270 110.1%  
Pledged promoter(s) holding % 36.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare VENUS REMEDIES With:   STRIDES SHASUN LTD  AJANTA PHARMA  UNICHEM LAB  DR. DATSONS LABS  CADILA HEALTHCARE  

Compare VENUS REMEDIES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens 99 Points Down; Vedanta & Coal India Top Losers(09:30 am)

Asian share markets are lower today as Japanese and Hong Kong shares fall. The Nikkei 225 is off 0.9% while the Hang Seng is down 2%. The Shanghai Composite is trading down by 2.7%.

Related Views on News

VENUS REMEDIES Announces Quarterly Results (4QFY18); Net Profit Down 307.2%

Jun 12, 2018 | Updated on Jun 12, 2018

For the quarter ended March 2018, VENUS REMEDIES has posted a net profit of Rs 94 m (down 307.2% YoY). Sales on the other hand came in at Rs 932 m (up 16.8% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Should You Get out of Small Caps Now... Before the Fall Worsens(Profit Hunter)

Jun 6, 2018

An almost zero-loss strategy that works best when markets correct. Don't let the current volatility overwhelm you. Focus on the fundamentals and long term, and buy stocks where quality meets value.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Jun 19, 2018 10:35 AM

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES 8-QTR ANALYSIS

COMPARE VENUS REMEDIES WITH

MARKET STATS